10x Genomics, Inc. v. Parse Biosciences, Inc.

Summary

The court affirmed the Board’s determinations that all challenged claims of the three patents were unpatentable as obvious over combinations of the cited prior art. It held that substantial evidence supported the Board’s findings of motivation to combine, disclosure of the claimed correlation limitations, and motivation to use ligation as a design choice. The court also concluded that 10x had not preserved one motivation-to-combine challenge and had not shown harmful error. The disposition is nonprecedential.